Ann Marie O'Neill/aum.edu
May 20, 2026, 08:03
Ann Marie O’Neill: Help Us Improve Information for DOAC Medicines
Ann Marie O’Neill, Operations Manager at The Meath Foundation , Thrombosis Patient Advocate, shared a post on LinkedIn:
“We are inviting people who take Direct Oral Anticoagulant Medication (DOAC) eg. Apixaban (Eliquis) Rivaroxaban (Xaralto) or Dabigatran (Pradaxa) after experiencing a blood clot, to join a small focus group to help us improve our Patient information booklet.
If you are a VTE Health Care Professional, please share with your relevant Patients.
The more the merrier.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026